Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.
(Aromatase inhibitors)
13,057 results
  • [A real-world study of the effects of endocrine therapy on liver function in breast cancer]. [Journal Article]
    Zhonghua Wai Ke Za Zhi. 2023 Feb 01; 61(2):107-113.Li YC, Deng ZX, … Shen SJ
  • Objective: To compare the effect of different endocrine therapy drugs on liver function in patients with early breast cancer. Methods: A retrospective cohort study was conducted to include 4 318 patients with early breast cancer who received adjuvant endocrine therapy in Department of Breast Surgery, Peking Union Medical College Hospital from January 1, 2013 to December 31, 2021. All the patients…
  • Management of bone loss due to endocrine therapy during cancer treatment. [Review]
    Osteoporos Int. 2023 Jan 19 [Online ahead of print]Khan MI
  • Bone modifying agents BMAs (oral and IV bisphosphonates, denosumab) are used to treat bone loss due to endocrine therapy in patients with hormone receptor positive (HR +) early breast cancer and non-metastatic prostate cancer (NMPC). Timely initiation of appropriate sequential therapy is imperative to reduce cancer treatment-induced bone loss (CTIBL). This narrative review summarizes current lite…
  • Review of bone health in women with estrogen receptor-positive breast cancer receiving endocrine therapy. [Review]
    Womens Health (Lond). 2023 Jan-Dec; 19:17455057221149493.Malagrinò M, Zavatta G
  • In estrogen-receptor-positive tumors, adjuvant endocrine therapy has been shown to be highly beneficial for both overall and disease-free survival. Estradiol is key in regulating bone and mineral physiology, and several studies found a strong correlation between these therapies and the risk of fractures. Since these therapies are often given for 5 through 10 years, the timing for bisphosphonates …
  • Apoptosis-modulatory miR-361-3p as a novel treatment target in endocrine-resistant breast cancer. [Journal Article]
    J Endocrinol. 2023 Jan 01 [Online ahead of print]Zamarbide Losada J, Sulpice E, … Fletcher CE
  • Breast cancer (BC) is the most diagnosed cancer in women worldwide. In estrogen receptor (ER)-positive disease, anti-estrogens and aromatase inhibitors (AI) improve patient survival, however many patients develop resistance. Dysregulation of apoptosis is a common resistance mechanism, thus agents that can reinstate activity of apoptotic pathways represent promising therapeutics for advanced drug-…
  • Synthesis, antiproliferative evaluation and in silico studies of a novel steroidal spiro morpholinone. [Journal Article]
    Steroids. 2023 Jan 06; 192:109173.Cobos-Ontiveros LA, Romero-Hernández LL, … Montiel-Smith S
  • Estrogens play a pivotal role in the development of estrogen-dependent breast cancer and other hormone-dependent disorders. A common strategy to overcome the pathological effects of estrogens is the use of aromatase inhibitors (AIs), which bind to the enzyme and prevent the union with the natural substrate, decreasing the amount of estrogens produced. Several AIs have been developed, including in…
New Search Next